Corcept Therapeutics Inc. (CORT)

Price$72.62

Value ScoreF

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-16.46%

Price vs S&P 500 (4W)38.92%

VGM Score43.59

Market Capitalization$7.80B

P/E Ratio (Annual)78.23x

All Metrics

P/CF (Annual)54.90x

Book Value / Share (Quarterly)$5.94

P/TBV (Annual)5.18x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)23.74%

Cash Flow / Share (Quarterly)$1.12

Price vs S&P 500 (YTD)100.52%

Gross Margin (TTM)98.25%

Net Profit Margin (TTM)6.16%

EPS (TTM)$0.35

10-Day Avg Trading Volume0.96M

EPS Excl Extra (TTM)$0.35

Revenue Growth (5Y)16.56%

EPS (Annual)$0.83

ROI (Annual)15.38%

Gross Margin (Annual)98.30%

Net Profit Margin (5Y Avg)22.40%

Cash / Share (Quarterly)$3.20

P/E Basic Excl Extra (TTM)164.66x

Revenue Growth QoQ (YoY)4.89%

EPS Growth (5Y)-0.54%

P/E Normalized (Annual)78.23x

ROA (Last FY)11.91%

Revenue Growth TTM (YoY)12.20%

EBITD / Share (TTM)$-0.06

ROE (5Y Avg)21.45%

Operating Margin (TTM)-1.07%

Cash Flow / Share (Annual)$1.34

P/B Ratio12.22x

P/B Ratio (Quarterly)6.76x

Net Income / Employee (Annual)$136,500

EV / Revenue (TTM)9.99x

Net Interest Coverage (TTM)106.60x

ROA (TTM)5.78%

EPS Growth QoQ (YoY)-21.52%

EV / EBITDA (TTM)167.31x

EPS Incl Extra (Annual)$0.83

Current Ratio (Annual)2.92x

Quick Ratio (Quarterly)2.64x

3-Month Avg Trading Volume1.57M

52-Week Price Return5.23%

EV / Free Cash Flow (Annual)54.22x

P/E Incl Extra (TTM)164.66x

Revenue / Employee (TTM)$1,053,600

Tangible BV / Share (Quarterly)$4.48

P/S Ratio (Annual)10.24x

Asset Turnover (Annual)0.91x

52-Week High$91.00

Operating Margin (5Y Avg)22.09%

EPS Excl Extra (Annual)$0.83

CapEx CAGR (5Y)-29.36%

Tangible BV CAGR (5Y)21.32%

26-Week Price Return-8.54%

Quick Ratio (Annual)2.71x

13-Week Price Return113.34%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.86x

Enterprise Value$7.69B

Revenue / Share Growth (5Y)17.37%

Asset Turnover (TTM)0.94x

Book Value / Share Growth (5Y)6.39%

Revenue / Employee (Annual)$1,043,000

Inventory Turnover (Annual)1.03x

Pretax Margin (Annual)8.73%

Cash / Share (Annual)$3.56

3-Month Return Std Dev63.02%

Gross Margin (5Y Avg)98.51%

Net Income / Employee (TTM)$64,900

EBITDA CAGR (5Y)-18.62%

EBITDA Interim CAGR (5Y)-31.03%

ROE (Last FY)15.38%

Net Interest Coverage (Annual)19.77x

EPS Basic Excl Extra (Annual)$0.83

P/FCF (TTM)54.98x

Receivables Turnover (TTM)15.25x

EV / Free Cash Flow (TTM)64.17x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.35

Receivables Turnover (Annual)13.39x

ROI (TTM)7.42%

P/S Ratio (TTM)10.14x

Pretax Margin (5Y Avg)24.31%

Revenue / Share (Annual)$6.35

Tangible BV / Share (Annual)$3.83

Forward P/E60.30x

Free OCF CAGR (5Y)-1.23%

Price vs S&P 500 (52W)-19.13%

P/E Ratio (TTM)164.66x

EPS Growth TTM (YoY)-69.52%

Year-to-Date Return108.68%

5-Day Price Return3.09%

EPS Normalized (Annual)$0.83

ROA (5Y Avg)17.94%

Net Profit Margin (Annual)13.09%

Month-to-Date Return4.50%

Cash Flow / Share (TTM)$0.81

EBITD / Share (Annual)$0.38

EPS Growth (3Y)-1.69%

Operating Margin (Annual)5.88%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)64.91x

ROI (5Y Avg)21.45%

P/E Excl Extra (TTM)164.66x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$0.35

P/TBV (Quarterly)5.63x

P/B Ratio (Annual)11.40x

Inventory Turnover (TTM)0.99x

Pretax Margin (TTM)1.58%

Book Value / Share (Annual)$6.11

Price vs S&P 500 (13W)105.08%

Net Margin Growth (5Y)-15.26%

Beta0.52x

P/FCF (Annual)54.98x

Revenue / Share (TTM)$7.36

ROE (TTM)7.42%

52-Week Low$28.66

vGradeF

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.30est. -0.02

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.75

3.92

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
CORTCorcept Therapeutics Inc.	F	C	B	$72.62
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Corcept Therapeutics is a pharmaceutical company developing cortisol-modulating medications for metabolic, oncologic, and neuropsychiatric disorders. The company commercializes Korlym (mifepristone) for hypercortisolism (Cushing's syndrome), with a clinical-stage pipeline including compounds targeting multiple solid tumors, ALS, and MASH.